Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies

Mauricio Tohen, MD, DrPH, MBA; Michael Case, MS; Madhukar H. Trivedi, MD; Michael E. Thase, MD; Scott J. Burke, MS; and Todd M. Durell, MD

Published: February 23, 2010

Article Abstract

Objective: To characterize response profiles
of olanzapine/fluoxetine combination therapy in
treatment-resistant depression (TRD) and to investigate predictive relationships of early improvement with
olanzapine/fluoxetine combination for subsequent
response/remission during the acute phase of treatment.

Method: Results were pooled from 5 outpatient studies comparing oral olanzapine/fluoxetine combination, fluoxetine, or olanzapine for a maximum of 8 weeks in patients with TRD who had at least 1 historical antidepressant treatment failure during the current episode and who failed a prospective antidepressant therapy during the study lead-in period. Mean
Montgomery-Asberg Depression Rating Scale (MADRS) total and core mood items scores from the 8-week evaluation period were compared across treatment groups. Positive and negative predictive values (PPVs, NPVs) were computed from olanzapine/fluoxetine combination-treated patients demonstrating response and remission based on whether they demonstrated early improvement.

Results: Mean olanzapine/fluoxetine combination MADRS score reductions were significantly greater than fluoxetine by week 0.5 and olanzapine by week 1. Significantly more olanzapine/fluoxetine combination patients demonstrated MADRS onset of response compared with fluoxetine and olanzapine patients (P‘ ‰<‘ ‰.001 for both MADRS total and core mood items). In
olanzapine/fluoxetine combination patients, 38.1% exhibited MADRS total score response versus 26.9% of fluoxetine patients (P‘ ‰<‘ ‰.001) and 22.2% of olanzapine patients (P‘ ‰<‘ ‰.001). NPVs for MADRS total and core mood items response and remission ranged from 85.7% to 92.1%; PPVs ranged from 29.9% to 45.1%.

Conclusions: Olanzapine/fluoxetine combination is superior to fluoxetine and olanzapine in producing early improvement in patients with TRD. The absence of early improvement is highly predictive for overall response failure.

Trial Registration: clinicaltrials.gov Identifier: NCT00035321

J Clin Psychiatry

Submitted: December 23, 2008; accepted October 19, 2009.

Online ahead of print: February 23, 2010.

Corresponding author: Mauricio Tohen, MD, DrPH, MBA, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 (tohen@uthscsa.edu).

Volume: 71

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...